Research progress of growth hormone in the treatment of small for gestational age infants

doi:10.11852/zgetbjzz2023-0634

Abstract

Abstract: Generally, small for gestational age(SGA) infants will catch up with growth after birth, but some SGAs fail to show enough catch-up growth, leading to physical growth backwardness, and the risk of metabolic diseases in adult offspring increases. The application of exogenous growth hormone replacement therapy can ensure and promote the occurrence of SGA catching up with growth. However, as growth hormone exerts therapeutic effects in related clinical diseases, clinical attention is gradually being paid to whether growth hormone may bring long-term risks. This article aims to review the efficacy and potential risks of growth hormone treatment for SGA.

Key words: small for gestational age, catch-up growth, growth hormone

摘要： 通常情况下小于胎龄(SGA)儿在出生之后会发生追赶生长,但有部分SGA儿未能表现出足够的追赶生长,导致体格生长落后,并且成年后代谢性疾病风险增加。应用外源性生长激素替代治疗可保证和促进SGA儿追赶生长的发生,但随着生长激素在相关临床疾病发挥疗效的同时,生长激素是否可能带来长期风险亦逐步被临床关注,本文拟对生长激素治疗SGA的疗效和可能风险进行综述。

关键词: 小于胎龄儿, 追赶生长, 生长激素

CLC Number:

LIN Kunhong, CHEN Dijia, XING Yan, WANG Xinli. Research progress of growth hormone in the treatment of small for gestational age infants[J]. Chinese Journal of Child Health Care, 2024, 32(4): 419-423.

林坤鸿, 陈迪嘉, 邢燕, 王新利. 生长激素治疗小于胎龄儿的研究进展[J]. 中国儿童保健杂志, 2024, 32(4): 419-423.

References

[1] Physical status: The use and interpretation of anthropometry. Report of a WHO Expert Committee[J]. World Health Organization Technical Report Series, 1995, 854: 1-452.
[2] Clayton PE, Cianfarani S, Czernichow P, et al. Management of the child born small for gestational age through to adulthood: A consensus statement of the international societies of pediatric endocrinology and the growth hormone research society[J]. J Clin Endocrinol Metab, 2007, 92(3): 804-810.
[3] 首都儿科研究所,九市儿童体格发育调查协作组. 中国不同出生胎龄新生儿出生体重、身长和头围的生长参照标准及曲线[J]. 中华儿科杂志, 2020,58(9):738-746.
Capital Institute of Pediatrics, the Coordinating Study Group of Nine Cities on the Physical Growth and Development of Children. Growth standard curves of birth weight, length and head circumference of Chinese newborns of different gestation[J]. Chin J Pediatr, 2020, 58(9): 738-746.(in Chinese)
[4] 中华医学会围产医学分会胎儿医学学组.中华医学会妇产科学分会产科学组.胎儿生长受限专家共识(2019版)[J].中华围产医学杂志, 2019, 22(6): 361-380.
Fetal Medicine Subgroup, Society of Perinatal Medicine, Chinese Medical Association. Obstetrics Subgroup, Society of Obstetrics and Gynecology, Chinese Medical Association. Expert consensus on fetal growth restriction[J]. Chin J Perinatal Medicine, 2019, 22(6): 361-380.(in Chinese)
[5] Blake RA, Park S, Baltazar P, et al. LBW and SGA impact longitudinal growth and nutritional status of filipino infants[J].PLoS One, 2016, 11(7): e0159461.
[6] Boersma B, Wit JM. Catch-up growth[J]. Endocr Rev,1997,18(5):646-661.
[7] Reiter E, Rosenfeld RG. Williams textbook of endocrinology[M]. Philadelphia, PA,USA: Saunders/Elsevier, 2007.
[8] Martínez JI, Román EM, Alfaro EL, et al. Geographic altitude and prevalence of underweight, stunting and wasting in newborns with the INTERGROWTH-21st standard[J]. Pediatr(Rio J), 2019, 95(3): 366-373.
[9] Zhang L, Li Y, Liang S, et al. Postnatal length and weight growth velocities according to fenton reference and their associated perinatal factors in healthy late preterm infants during birth to term-corrected age: An observational study[J]. Ital J Pediatr, 2019, 45(1): 1.
[10] Marcovecchio ML, Gorman S, Watson LPE, et al. Catch-up growth in children born small for gestational age related to body composition and metabolic risk at six years of age in the UK[J]. Horm Res Paediatr, 2020, 93(2): 119-127.
[11] Lavi E, Shafrir A, Halloun R, et al.Eligibility for growth hormone therapy in children born small for gestational age is substantially lower than expected[J]. Clin Endocrinol(Oxf), 2021, 95(2): 308-314.
[12] Zhou E, Hauser BR, Jee YH. Genetic evaluation in children with short stature[J]. Curr Opin Pediatr, 2021, 33(4): 458-463.
[13] Cameron N. The human growth curve, canalization and catch-up growth [M]//Human growth and development. Salt Lake City: Academic Press, 2012: 1-22.
[14] Ou-Yang MC, Sun Y, Liebowitz M, et al. Accelerated weight gain, prematurity, and the risk of childhood obesity: A Meta-analysis and systematic review[J]. PLoS One, 2020, 15(5): e0232238.
[15] Santiago ACT, Cunha LPMD, Costa ML, et al. Cardiometabolic evaluation of small for gestational age children:Protective effect of breast milk[J]. Nutr Hosp, 2021, 38(1): 36-42.
[16] Hofi L, Flidel-Rimon O, Hershkovich-Shporen C, et al.Differences in growth patterns and catch up growth of small for gestational age preterm infants fed on fortified mother's own milk versus preterm formula[J]. Br J Nutr, 2022,129(12):1-24.
[17] Renes JS, van Doorn J, Hokken-Koelega ACS. Currentinsights into the role of the growth hormone-insulin-like growth factor system in short children born small for gestational age[J]. Horm Res Paediatr, 2019,92(1): 15-27.
[18] Hindmarsh P. Normal growth and its endocrine control[M]. Clinical Paediatric Endocrinology Oxford: Blackwell Scientific Publications,1989: 57-73.
[19] de Waal WJ, Hokken-Koelega AC, Stijnen T, et al. Endogenous and stimulated GH secretion, urinary GH excretion, and plasma IGF-Ⅰ and IGF-Ⅱ levels in prepubertal children with short stature after intrauterine growth retardation. The dutch working group on growth hormone[J]. Clin Endocrinol(Oxf), 1994, 41(5): 621-630.
[20] Boguszewski M, Rosberg S, Albertsson-Wikland K. Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children[J]. J Clin Endocrinol Metab, 1995, 80(9): 2599-2606.
[21] Renes JS, van Doorn J, Hokken-Koelega ACS. Currentinsights into the role of the growth hormone-insulin-like growth factor system in short children born small for gestational age[J]. Horm Res Paediatr, 2019, 92(1):15-27.
[22] Blyth AJ, Kirk NS, Forbes BE. Understanding IGF-Ⅱ action through insights into receptor binding and activation[J]. Cells, 2020, 9(10): 2276.
[23] Onuma S, Ida S, Maeyama T, et al. Growth hormone treatment for extremely low birthweight children born small for gestational age[J]. Pediatr Int, 2021, 63(1): 46-52.
[24] Adler E, Lambert AS, Bouvattier C, et al. Determinants offinal height in patients born small for gestational age treated with recombinant growth hormone[J]. Horm Res Paediatr, 2021, 94(1-2): 52-62.
[25] Labarta JI, de Arriba A, Ferrer M, et al. Growth and metabolic effects of long-term recombinant human growth hormone(rhGH) treatment in short children born small for gestational age: GH-RAST study[J]. J Pediatr Endocrinol Metab, 2020, 33(7): 923-932.
[26] de Zegher F, Butenandt O, Chatelain P, et al. Growth hormone treatment of short children born small for gestational age:Reappraisal of the rate of bone maturation over 2 years and Meta analysis of height gain over 4 years[J]. Acta Paediatr Suppl, 1997, 423: 207-212.
[27] Horikawa R, Tanaka T, Nishinaga H, et al. Evaluation of growth hormone treatment efficacy in short Japanese children born small for gestational age: Five-year treatment outcome and impact on puberty[J]. Clin Pediatr Endocrino, 2017, 26(2):63-72.
[28] Moon JE, Ko CW. Delayed bone age might accelerate the response to human growth hormone treatment in small for gestational age children with short stature[J]. Int J Endocrinol, 2019, 2019:8454303.
[29] Smeets CCJ, van der Steen M, Renes JS, et al.Bonemineral density after cessation of GH treatment in young adults born SGA: A 5-year longitudinal study[J]. J Clin Endocrinol Metab, 2017, 102(9):3508-3516.
[30] Goedegebuure WJ, van der Steen M, Kerkhof GF, et al. Longitudinal study on metabolic health in adults SGA during 5 years after GH with or without 2 years of GnRHa treatment[J]. J Clin Endocrinol Metab, 2020,105(8):287.
[31] van der Steen M, Smeets CC, Kerkhof GF, et al. Metabolic health of young adults who were born small for gestational age and treated with growth hormone, after cessation of growth hormone treatment:A 5-year longitudinal study[J]. Lancet Diabetes Endocrinol, 2017, 5(2): 106-116.
[32] Tidblad A, Bottai M, Kieler H, et al. Association ofchildhood growth hormone treatment with long-term cardiovascular morbidity[J]. JAMA Pediatr, 2021, 175(2): e205199.
[33] van der Steen M, Kerkhof GF, Smeets CCJ, et al. Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment:A 5-year longitudinal study[J]. Lancet Diabetes Endocrinol, 2017, 5(12): 975-985.
[34] Pivonello R, Di Somma C, Colao A. Cardiovascular risk after cessation of growth hormone treatment in people born small for gestational age[J]. Lancet Diabetes Endocrinol, 2017, 5(12): 930-932.
[35] Quigley CA, Child CJ, Zimmermann AG, et al. Mortality inchildren receiving growth hormone treatment of growth disorders: Data from the genetics and neuroendocrinology of short stature international study[J]. J Clin Endocrinol Metab, 2017, 102(9): 3195-3205.
[36] Sävendahl L, Cooke R, Tidblad A, et al. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study[J]. Lancet Diabetes Endocrinol, 2020, 8(8): 683-692.
[37] Sävendahl L, Polak M, Backeljauw P, et al. Long-term safety of growth hormone treatment in childhood: Two large observational studies: NordiNet IOS and ANSWER[J]. J Clin Endocrinol Metab, 2021, 106(6): 1728-1741.